Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Amphastar Pharmaceuticals (AMPH) Invested Capital: 2013-2025

Historic Invested Capital for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $1.1 billion.

  • Amphastar Pharmaceuticals' Invested Capital rose 4.57% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 4.57%. This contributed to the annual value of $1.1 billion for FY2024, which is 9.43% up from last year.
  • As of Q3 2025, Amphastar Pharmaceuticals' Invested Capital stood at $1.1 billion, which was up 1.75% from $1.1 billion recorded in Q2 2025.
  • In the past 5 years, Amphastar Pharmaceuticals' Invested Capital registered a high of $1.1 billion during Q3 2025, and its lowest value of $459.4 million during Q1 2021.
  • For the 3-year period, Amphastar Pharmaceuticals' Invested Capital averaged around $1.0 billion, with its median value being $1.1 billion (2024).
  • In the last 5 years, Amphastar Pharmaceuticals' Invested Capital surged by 91.77% in 2023 and then dropped by 2.84% in 2024.
  • Quarterly analysis of 5 years shows Amphastar Pharmaceuticals' Invested Capital stood at $515.1 million in 2021, then grew by 15.89% to $596.9 million in 2022, then soared by 64.92% to $984.4 million in 2023, then grew by 9.43% to $1.1 billion in 2024, then increased by 4.57% to $1.1 billion in 2025.
  • Its Invested Capital stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $1.1 billion for Q1 2025.